SCI Pharmtech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 09, 2023
Share
SCI Pharmtech, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 257.85 million compared to TWD 304.59 million a year ago. Revenue was TWD 257.85 million compared to TWD 304.59 million a year ago. Net income was TWD 35.38 million compared to TWD 48.62 million a year ago. Basic earnings per share from continuing operations was TWD 0.33 compared to TWD 0.45 a year ago. Diluted earnings per share from continuing operations was TWD 0.33 compared to TWD 0.45 a year ago.
For the nine months, sales was TWD 912.74 million compared to TWD 673.97 million a year ago. Revenue was TWD 912.74 million compared to TWD 673.97 million a year ago. Net income was TWD 298.33 million compared to TWD 230.13 million a year ago. Basic earnings per share from continuing operations was TWD 2.78 compared to TWD 2.14 a year ago. Diluted earnings per share from continuing operations was TWD 2.77 compared to TWD 2.14 a year ago.
SCI Pharmtech, Inc. is a Taiwan-based company principally engaged in the processing, manufacture and sales of Active Pharmaceutical Ingredients (APIs). The Company's main products include APIs, API intermediates and special and precision chemicals. The Company distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
SCI PHARMTECH, INC. 
